Screening for gestational disorders

Details Screening for gestational disorders Screening for gestational disorders

2008-01-29

2008-01-29

Le, Long V. (Department: 1641)

Chemistry: analytical and immunological testing

Involving an insoluble carrier for immobilizing immunochemicals

C435S007100, C436S811000

Reexamination Certificate

active

10920116

ABSTRACT:
The invention relates to methods and compositions for identifying pregnant subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy, and as early as the first trimester.

REFERENCES:
patent: 5516702 (1996-05-01), Senyei et al.
patent: 5580554 (1996-12-01), Keith
patent: 6461830 (2002-10-01), Parrott
patent: 2002/0102530 (2002-08-01), Keith, Jr. et al.
patent: 2002/0110833 (2002-08-01), Caniggia et al.
patent: 2004/0053325 (2004-03-01), Breit et al.
patent: 2004/0126828 (2004-07-01), Karumanchi et al.
Janeway C, Travers P, Walport M, Capra JD. 1999. Immunobiology: The Immune System in Health and Disease. New York, NY: Elsevier Science Ltd./Garland Publishing, pp. 197-198, 266-269, 288-293, 588-591, 593, 598, and 604.
Bowen et al. “Cytokines of the Placenta and Extra-placental Membranes: Roles and Regulation During Human Pregnancy and Parturition” (2002) Placenta 23:257-273.
Stiemer et al. “Interleukin-8 in urine: a new diagnostic parameter for intra-amniotic infection after premature rupture of the membranes” (1997) British Journal of Obstetrics and Gynaecology 104:499-502.
Kauma et al. “Increased Endothelial Monocyte Chemoattractant Protein-1 and Interleukin-8 in Preeclampsia” (2002) Obstet Gynecol. 100:706-714.
The American Physiological Society, “Guidelines for Reporting Statistics in Journals Published by the American Physiological Society” J Neurophysiol 92:669-671, 2004.
Tikhonov et al., “A study of interleukin-8 and defensins in urine and plasma of patients with pyelonephritis and glomerulonephritis” Neph. Dial. Transplant. 12(12):2557-61 (1997).
Djurovic et al., “Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia,” BJOG 109(7):759-64 (2002).
Bartha et al., “The relationships between leptin and inflammatory cytokines in women with pre-eclampsia,”British Journal of Obstetrics and Gynaecology, 108:1272-1276 (2001).
Benyo et al., “Expression of Inflammatory Cytokines in Placentas from Women with Preeclampsia,”J. Clin. Endocrinol. Metab., 86(6):2505-2512 (2001).
Benyo et al., “Hypoxia Stimulates Cytokine Production by Villous Explants from the Human Placenta,”J. Clin. Endocrinol. Metab., 82(5):1582-1588 (1997).
Denison et al., “Cytokine secretion by human fetal membranes, deciduas and placenta at term,”Hum. Reprod., 13(12):3560-3565 (1998).
“Findings from the 1992-98 Patient Outcomes Research Team on Low Birthweight,” Agency for Healthcare Research and Quality, http://www.ahcpr.gov/clinic/lobrhigh.htm, 3 pages (May 28, 2003).
Hæger et al., “Increased release of tumor necrosis factor-alpha and interleukin-6 in women with the syndrome of hemolysis, elevated liver enzymes, and low platelet count,”Acta. Obstet. Gynecol. Scand., 75:695-701 (1996).
Lappas et al., “Regulation of Proinflammatory Cytokines in Human Gestational Tissues by Peroxisome Proliferator-Activated Receptor-γ. Effect of 15-Deoxy-Δ12,14-PGJ2and Troglitazone,”J. Clin. Endocrinol. Metab., 87(10):4667-4672 (2002).
Matthiesen, “Immune Changes in Pregnancy—A Survey of some Immunological Variables in Normal and Complicated Pregnancies,” Linköping University Medical Dissertations No. 563, http://www.bibl.liu.se/liupubl/disp/disp98/med563s.htm, 2 pages (May 28, 2003).
Omu et al., “Connection between human leucocyte antigens D region and T helper cytokines in preeclampsia,”Arch. Gynecol. Obstet., 269(2):79-84 (2004; published online Nov. 7, 2002).
Smulian et al., “Intrapartum fever at term: Serum and histologic markers of inflammation,”Am. J. Obstet. Gynecol., 188(1):269-274 (2003).
Takacs et al., “Increased vascular endothelial cell production of interleukin-6 in severe preeclampsia,”Am. J. Obstet. Gynecol., 188(3):740-744 (2003).
Velzing-Aarts et al., “High Serum Interleukin-8 Levels in Afro-Caribbean Women with Pre-eclampsia. Relations with Tumor Necrosis Factor-α, Duffy Negative Phenotype and Von Willebrand Factor,”Am. J. Reprod. Immunol., 48:319-322 (2002).
Seely and Solomon, “Insulin Resistance and its Potential Role in Pregnancy-Induced Hypertension,”The Journal of Clinical Endocrinology&Metabolism, vol. 88(6), pp. 2393-2398, (2003).
Levine et al., “Circulating Angiogenic Factors and the Risk of Preeclampsia,”The New England Journal of Medicine, vol. 350, pp. 672-683, (2004).
Polliotti et al., “Second-Trimester Maternal Serum Placental Growth Factor and Vascular Endothelial Growth Factor for Predicting Severe, Early-Onset Preeclampsia,”The American College of Obstetricians and Gynecologists, vol. 101, No. 6, pp. 1266-1274, (2003).
Taylor et al., “Longitudinal Serum Concentrations of Placental Growth Factor: Evidence for Abnormal Placental Angiogenesis in Pathologic Pregnancies,”American Journal Obstetricians and Gynecologists, vol. 188, pp. 177-182 (2003).
Thadhani et al., “Insulin Resistance and Alternations in Angiogenesis Additive Insults That May Lead to Preeclampsia,”Hypertension, vol. 43, pp. 988-992, (2004).
Tidwell et al., “Low Maternal Serum Levels of Placenta Growth Factor as an Antecedent of Clinical Preeclampsia,”American Journal Obstetricians and Gynecologists, vol. 184, pp. 1267-1272 (2001).
Wolf et al., “First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective Study,”The Journal of Clinical Endocrinology&Metabolism, vol. 87(4), pp. 1563-1568, (2002).
Wolf et al., “Insulin Resistance But Not Inflammation is Associated with Gestational Hypertension,”Hypertension, vol. 40, pp. 886-891, (2002).
Wolf et al., “Preeclampsia and Future Cardiovascular Disease: Potential Role of Altered Angiogenesis and Insulin Resistance,”The Journal of Clinical Endocrinology&Metabolism, vol. 89(12), pp. 6239-6243, (2004).
Rinehart et al., “Expression of the Placental Cytokines Tumor Necrosis Factor α, Interleukin 1β, and Interleukin 10 is Increased in Preeclampsia,”Am J Obstet Gynecol, Oct. 1999, pp. 915-920.
Thadhani et al., “First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia,”The journal of Clinical Endocrinology&Metabolism, 89(2), pp. 770-775, 2004.
Maynard et al., “Excess Placental Solube Fms-Like Tyrosine Kinase 1 (sFlt1) may Contribute to Endothelial Dysfunction, Hypertension, and Proteinuria in Preeclampsia,”The Journal of Clinical Investigation, Mar. 2003, vol. 111, No. 5, pp. 1-10.
Page et al., “Placental Peptides as Markers of Gestational Disease,”Reproduction(2002) 123, 487-495.
Massé et al., “A Prospective Study of Several Potential Biologic Markers for Early Prediction of the Development of Preeclampsia,”Am J Obstet Gynecol, vol. 169, No. 3, pp. 501-508, 1993.
Heikkinen et al., “Cytokine Levels in Midtrimester Amniotic Fluid in Normal Pregnancy and in the Prediction of Pre-Eclampsia,”Scand. J. Immunol, 53, 310-314, 2001.
Helske et al., “Expression of Vascular Endothelial Growth Factor Receptors 1, 2 and 3 in Placentas From Normal and Complicated Pregnancies,”Molecular Human Reproduction, vol. 7, No. 2, pp. 205-210, 2001.

Affiliated with

Also associated with

Rating

Screening for gestational disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Screening for gestational disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening for gestational disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3932648